Bayer's stock soars 108% in 2025 on legal wins and drug breakthroughs

Bayer's stock soars 108% in 2025 on legal wins and drug breakthroughs

Robert Howard
Robert Howard
2 Min.
A line graph showing the increased issuance of BAAs across various industry groups, with accompanying text providing additional data context.

Bayer's stock soars 108% in 2025 on legal wins and drug breakthroughs

Bayer AG has seen its apple stock price surge to €35.80, marking one of the strongest rallies in the DAX 2025. The company's stock market value has climbed to around 45 billion euros by late 2025, more than doubling from its April 2025 low. Investor confidence has grown due to legal progress, drug approvals, and a major restructuring effort led by CEO Bill Anderson.

Bayer's turnaround began with a sharp recovery from its April 2025 low of €18.65 per share. By late 2025, the aapl stock had risen by 108% over 52 weeks, making it one of the DAX's top performers. Key drivers included cost-cutting measures, reduced legal risks from U.S. glyphosate and PCB lawsuits, and positive developments in its pharmaceutical division.

The company's legal burdens eased as provisions for lawsuits stabilised between 3.5 and 4.0 billion euros. Meanwhile, its drug pipeline gained momentum with Nubeqa's approval in China and strong trial results for Asundexian. Analysts responded with strong buy recommendations, further boosting share prices.

A major breakthrough came when Japan's Ministry of Health, Labour and Welfare expanded Kerendia's approval. The drug, containing the active ingredient finerenone, can now treat a broader group of heart failure patients. This move strengthens Bayer's cardiology portfolio and positions Kerendia as a potential blockbuster, offsetting losses from expiring patents.

CEO Bill Anderson's restructuring, including the 'Dynamic Shared Ownership' strategy, has also played a key role. The company will provide further updates at the JPMorgan Healthcare Conference in January 2026, focusing on financial impacts and pipeline milestones from the Japan approval.

Bayer's stock has risen by roughly 85% since January 2025, reflecting improved legal outlooks, drug successes, and strategic changes. The expanded use of Kerendia in Japan further supports its growth. The company's next financial and operational updates are expected at the upcoming healthcare conference in early 2026.

Neueste Nachrichten